TacticScaleWhat Dexcom Does & How It Makes Money (DXCM)
Updated October 2026 · reflects Dexcom's latest reported financials
Maker of continuous glucose monitoring systems for diabetes management. DexCom makes money selling its CGM systems and sensors, marketing them directly to endocrinologists, physicians, and diabetes educators in the U.S.
How Dexcom makes money
DexCom makes money selling its CGM systems and sensors, marketing them directly to endocrinologists, physicians, and diabetes educators in the U.S. and internationally. Its Share remote monitoring system and Follow app add to the product lineup.
What Dexcom does
DexCom, Inc. is a San Diego-based medical device company that designs, develops, and sells continuous glucose monitoring (CGM) systems for managing diabetes and metabolic health. Its lineup includes the integrated Dexcom G7 and G7 15 Day, the Dexcom G6, and Dexcom ONE+, which is meant to replace fingerstick blood glucose testing for diabetes treatment decisions. The company has also moved beyond insulin users with Stelo, a biosensor for adults with prediabetes and Type 2 diabetes who don't use insulin. Dexcom Share and the Dexcom Follow app add remote monitoring. DexCom sells in the U.S. and internationally, marketing directly to endocrinologists, physicians, and diabetes educators. It was incorporated in 1999.
Products & services
- Dexcom G7 / G7 15 Day
- Dexcom G6
- Dexcom ONE+
- Stelo
- Dexcom Share
- Dexcom Follow
What is Dexcom worth?
On an owner-earnings DCF, Dexcom's most-likely value is about $145 versus a recent price near $84 (72% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$41) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
GlucoTrack (GCTK) · Tandem Diabetes Care (TNDM) · Sinocare (300298.SZ) · Insulet (PODD) · Medtronic (MDT)